In 236 children with sickle cell disease and conditional cerebral blood flow velocity, voxelotor reduced velocity more than placebo at week 24 (−12.06 vs −4.29 cm/s; p=0.0048), but deaths (8 vs 2) and crises (59.2% vs 37.9%) were higher; the trial was stopped.
RCTn = 236
Bello-Manga et al. HOPE Kids 2: Phase 3, Randomized Trial of Voxelotor in Children With SCD and Conditional Cerebral Blood Flow Velocities